RxDoctor Payments Data

Christine Johnston

Infectious Disease · Seattle, WANPI 1104928720

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $26,369 of the $26,799 with a category attached, or 98.4%. GSK accounts for 71.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $16,189 and has fallen 81.3% since, to $3,025 in 2025. Among infectious disease clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$26,799in general payments, 2019–2025

Across 10 payments — averaging $2679.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$19K
  • Pfizer$3K
  • AbbVie$3K
  • Gilead$2K
  • Modernatx, Inc.$395
  • EMD Serono, Inc.$34
$635,457in research payments, 2019–2025

Across 73 payments — averaging $8704.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Modernatx, Inc.$528K
  • GSK$103K
  • Pfizer$4K

What the payments were for

  • Consulting fees$26,36998%
  • Food & beverage$4292%

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK4$19,044
Pfizer1$3,025
AbbVie2$2,800
Gilead1$1,500
Modernatx, Inc.1$395
EMD Serono, Inc.1$34

How this compares

$26,799 in reported general payments places this provider in the 90th percentile of 186 infectious disease providers in Washington.

See all infectious disease providers in Washington

Other infectious disease in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →